Drug Trial Radar · NCT00504933
Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis
Last checked: Nov 20, 2026Latest source record: Apr 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
683
Actual
Start
May 2005
Primary completion
Nov 2005
Study completion Nov 2005
Sponsor
- Lead sponsor
- Faes Farma, S.A.Industry
- Sponsor type
- Industry
- First posted
- Jul 20, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of seasonal allergic rhinitis.
Conditions
- Seasonal Allergic Rhinitis
Interventions
bilastineDrug
20 mg (encapsulated) tablets QD/14days
CetirizineDrug
10 mg (encapsulated) tablets. QD/14 days
PlaceboDrug
(encapsulated) Tablets QD/14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under curve of total symptoms score (TSS) from basal visit to D14 visit, according to the patient's assessment on reflective symptoms.Time frame: 14 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.